Navigation Links
AMP comments at FDA meeting on array-based tests
Date:6/30/2010

Bethesda, MD (June 30, 2010): Today, the Association for Molecular Pathology (AMP) presented comments at the US Food & Drug Administration's public meeting on array-based cytogenetic tests. The FDA convened the meeting to seek answers to more than a dozen questions they had on how to evaluate the performance, interpret results and report findings of array-based cytogenetic tests for copy number variation (CNV).

AMP believes array-based cytogenetic tests provide much higher resolution than traditional karyotyping, with expansive capabilities to diagnose and identify causes of genetic syndromes due to chromosome abnormalities. The standard of care in molecular and cytogenetic laboratories as well as genetics clinics is shifting from traditional karyotyping to array-based cytogenomic analysis. "This new technology has provided diagnoses that would have otherwise not been possible with older methods," explained Dr. Mark Sobel, AMP Executive Director.

Professional societies, such as AMP, are currently working to develop professional practice guidelines to address many of the questions raised by the FDA that focus on interpreting and reporting results of array-based cytogenetic tests. AMP believes that the interpretation of these tests falls within the scope of professional practice and that while the FDA should evaluate the technology platform for analytical validity, the FDA does not need to review each possible CNV result. "It is important to remember that all testing is performed in the context of the phenotype of the patient, and interpretation of laboratory data is a collaboration between the clinical scientist and the treating physician," said Dr. Sobel. AMP encourages the FDA to partner with professional associations to collaborate on the best manner to standardize the use and reporting of array-based tests.

AMP believes that to advance the use of array-based cytogenetic tests, the molecular cytogenetic field needs to collect data on both the laboratory results and clinical information. Dr. Sobel added, "Such a database will enable the community to continually assess the validity of results and accelerate the understanding of the results." AMP encourages the government to fund clinical research to further explore the associations between array findings and health information.


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related biology news :

1. AVAC comments on NIAID decision not to move forward with PAVE 100 Trial
2. Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
3. AMP submits comments on SACGHS report
4. Society for General Microbiology 161st Meeting, University of Edinburgh
5. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
6. Colony collapse disorder symposium added to ESA Annual Meeting
7. Meeting real-world climate information needs of business, government
8. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
9. NAS Biodiversity and Extinction Meeting Dec. 7-8
10. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
11. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
Breaking Biology Technology: